<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282867</url>
  </required_header>
  <id_info>
    <org_study_id>11901</org_study_id>
    <secondary_id>R01NS050192</secondary_id>
    <nct_id>NCT00282867</nct_id>
  </id_info>
  <brief_title>Glucose Regulation in Acute Stroke Patients (GRASP) Study</brief_title>
  <official_title>Glucose Regulation in Acute Stroke Patients (GRASP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility, safety and preliminary efficacy of
      the use of insulin infusions as treatment for hyperglycemic acute ischemic stroke patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic stroke is a common, devastating and costly disease. Half of acute stroke patients
      have elevated glucose levels upon admission to the hospital, and hyperglycemia is associated
      with poor outcome for post-stroke patients. It is unclear if treatment of hyperglycemia or
      glucose lowering improves outcome, however, in animal stroke models and other human
      conditions, aggressive glucose lowering is beneficial.

      The goal of this multicenter trial is to determine if tight control of blood glucose is
      beneficial in hyperglycemic patients with acute ischemic stroke. In the trial, researchers
      will compare intravenous (IV) glucose insulin and potassium (GIK) therapy plus meal insulin
      to control therapy in 72 stroke patients.

      Participants will be randomly assigned to one of three groups—(1) the control group with a
      target glucose level of &lt;300mg/dL; (2) the tight control GIK plus meal insulin group with a
      target of &lt;110mg/dL; or (3) the loose control GIK plus meal insulin group with a target of
      &lt;200mg/dL—with all groups avoiding glucose levels of &lt;70mg/dL.

      The specific aims of this study are to collect preliminary data on the safety and feasibility
      of GIK for treatment of hyperglycemia in acute stroke patients, and to collect preliminary
      data comparing tight GIK therapy with loose GIK therapy and control therapy. Information
      learned in this study will compliment ongoing work and allow for maximum efficiency in the
      design of future treatment trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemic Events</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable 3 Month Modified Rankin</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Stroke</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>tight control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>target glucose level 70-110 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>loose control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>target glucose level 70 - 200 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>target level 70 - 300 mg/dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV glucose insulin and potassium, GIK</intervention_name>
    <description>The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.</description>
    <arm_group_label>tight control group</arm_group_label>
    <arm_group_label>loose control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>usual care</description>
    <arm_group_label>usual care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Clinical diagnosis of ischemic stroke defined as acute neurological deficit occurring
             in one or more major vessels.

          -  Must arrive at hospital and be able to begin treatment within 2 hours of established
             eligibility and this must be within 24 hours of symptom onset. - - Patients unable to
             report symptom onset time or those awakening with symptoms must use the time last
             known to be well as the onset time.

          -  Admission plasma glucose of &gt; 110 mg/dL.

        Exclusion Criteria:

          -  Renal dysfunction as defined by a serum creatinine of &gt;/=2.5 mg/dL at enrollment.

          -  Substantial pre-existing neurological or psychiatric illness that would confound
             neurological assessment.

          -  Patients who have received experimental therapy for the enrollment stroke.

          -  Pregnant females.

          -  Patients with other severe life threatening conditions that makes them unlikely to
             survive 90 days.

          -  Patients who are unable to follow the protocol or come back for 90-day followup.

          -  Patient has condition for which insulin infusion is the usual practice or the treating
             physician feels that there is an indication for insulin infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Johnston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia, Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>July 14, 2009</results_first_submitted>
  <results_first_submitted_qc>July 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2009</results_first_posted>
  <last_update_submitted>July 15, 2009</last_update_submitted>
  <last_update_submitted_qc>July 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Karen C. Johnston, MD, MSc, PI, Professor and Chair Department of Neurology</name_title>
    <organization>University of Virginia</organization>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>acute ischemic stroke</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>glucose</keyword>
  <keyword>insulin</keyword>
  <keyword>insulin and potassium therapy</keyword>
  <keyword>GIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tight Control Group</title>
          <description>target glucose level 70-110 mg/dL</description>
        </group>
        <group group_id="P2">
          <title>Loose Control Group</title>
          <description>target glucose level 70 – 200 mg/dL</description>
        </group>
        <group group_id="P3">
          <title>Usual Care Group</title>
          <description>target level 70 - 300 mg/dL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>d/c prior to prim outcome, 3 m f/u done</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tight Control Group</title>
          <description>target glucose level 70-110 mg/dL</description>
        </group>
        <group group_id="B2">
          <title>Loose Control Group</title>
          <description>target glucose level 70 – 200 mg/dL</description>
        </group>
        <group group_id="B3">
          <title>Usual Care Group</title>
          <description>target level 70 - 300 mg/dL</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Favorable 3 Month Modified Rankin</title>
        <description>3 month functional outcomes by modified Rankin (0 to 1) dichotomized as favorable versus not favorable outcome. Construct is functional handicap.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tight Control Group</title>
            <description>target glucose level 70-110 mg/dL</description>
          </group>
          <group group_id="O2">
            <title>Loose Control Group</title>
            <description>target glucose level 70 – 200 mg/dL</description>
          </group>
          <group group_id="O3">
            <title>Usual Care Group</title>
            <description>target level 70 - 300 mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Favorable 3 Month Modified Rankin</title>
          <description>3 month functional outcomes by modified Rankin (0 to 1) dichotomized as favorable versus not favorable outcome. Construct is functional handicap.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemic Events</title>
        <description>hypoglycemic events</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tight Control Group</title>
            <description>target glucose level 70-110 mg/dL</description>
          </group>
          <group group_id="O2">
            <title>Loose Control Group</title>
            <description>target glucose level 70 – 200 mg/dL</description>
          </group>
          <group group_id="O3">
            <title>Usual Care Group</title>
            <description>target level 70 - 300 mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events</title>
          <description>hypoglycemic events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Symptomatic Hypoglycemia</title>
        <description>symptomatic hypoglycemia (glucose &lt; 55 mg/dL)during treatment period</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tight Control Group</title>
            <description>target glucose level 70-110 mg/dL</description>
          </group>
          <group group_id="O2">
            <title>Loose Control Group</title>
            <description>target glucose level 70 – 200 mg/dL</description>
          </group>
          <group group_id="O3">
            <title>Usual Care Group</title>
            <description>target level 70 - 300 mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Hypoglycemia</title>
          <description>symptomatic hypoglycemia (glucose &lt; 55 mg/dL)during treatment period</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Target Glucose Concentration</title>
        <description>glucose in target range in first 24 hours</description>
        <time_frame>first 24 hours after initiation of treatment</time_frame>
        <population>Per protocol no analysis of this endpoint was performed in the &quot;usual care&quot; group.</population>
        <group_list>
          <group group_id="O1">
            <title>Tight Control Group</title>
            <description>target glucose level 70-110 mg/dL</description>
          </group>
          <group group_id="O2">
            <title>Loose Control Group</title>
            <description>target glucose level 70 – 200 mg/dL</description>
          </group>
          <group group_id="O3">
            <title>Usual Care Group</title>
            <description>target level 70 - 300 mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Target Glucose Concentration</title>
          <description>glucose in target range in first 24 hours</description>
          <population>Per protocol no analysis of this endpoint was performed in the &quot;usual care&quot; group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen C. Johnston, MD, MSc</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434 924-5323</phone>
      <email>kj4v@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

